Transgene SA

Transgene Reports Business, Pipeline and Financial Update for Q3 2024

07 Nov 2024 11:45:00 By Nasdaq GlobeNewswire

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

07 Nov 2024 11:45:00 By Nasdaq GlobeNewswire

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development

05 Nov 2024 01:30:00 By Nasdaq GlobeNewswire

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

14 Oct 2024 01:30:00 By Nasdaq GlobeNewswire

Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024

07 Oct 2024 02:00:00 By Nasdaq GlobeNewswire

Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025

24 Sep 2024 11:45:00 By Nasdaq GlobeNewswire

Availability of Transgene’s Half-Year Financial Report as of June 30, 2024

24 Sep 2024 11:45:00 By Nasdaq GlobeNewswire

2024 Half-Year Financial Report

24 Sep 2024 11:45:00 By Nasdaq GlobeNewswire

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments

14 Sep 2024 03:05:00 By Nasdaq GlobeNewswire

Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation

10 Sep 2024 01:30:00 By Nasdaq GlobeNewswire

Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024

09 Sep 2024 01:00:00 By Nasdaq GlobeNewswire

Transgene to Participate in HTID Conference and Investor Access Forum in Paris

05 Sep 2024 11:45:00 By Nasdaq GlobeNewswire

Transgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 published in JITC

27 Aug 2024 01:30:00 By Nasdaq GlobeNewswire

Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024

22 Jul 2024 02:00:00 By Nasdaq GlobeNewswire

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2024

10 Jul 2024 12:00:00 By Nasdaq GlobeNewswire

Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer

03 Jun 2024 01:30:00 By Nasdaq GlobeNewswire

Transgene’s Combined General Meeting of May 15, 2024

15 May 2024 11:45:00 By Nasdaq GlobeNewswire

Transgene provides business and financial update for Q1 2024

14 May 2024 11:45:00 By Nasdaq GlobeNewswire

Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024

24 Apr 2024 11:45:00 By Nasdaq GlobeNewswire

Availability of Transgene's 2023 Universal Registration Document

11 Apr 2024 11:45:00 By Nasdaq GlobeNewswire